Edition:
United States

ImmunoGen Inc (IMGN.O)

IMGN.O on Nasdaq

6.55USD
22 Sep 2017
Change (% chg)

$0.05 (+0.77%)
Prev Close
$6.50
Open
$6.49
Day's High
$6.64
Day's Low
$6.43
Volume
1,555,178
Avg. Vol
3,431,556
52-wk High
$8.84
52-wk Low
$1.51

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target... (more)

Overall

Beta: 2.36
Market Cap(Mil.): $735.04
Shares Outstanding(Mil.): 112.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock

* ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock

Sep 01 2017

BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products

* Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products

Aug 29 2017

BRIEF-Jazz Pharmaceuticals and Immunogen announce strategic collaboration and option agreement

* Jazz Pharmaceuticals and Immunogen Inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Polygon Management Ltd reports 5.2 pct passive stake in Immunogen Inc - SEC Filing

* Polygon Management Ltd reports 5.2 percent passive stake in Immunogen Inc, as of August 2, 2017 - SEC Filing Source text: (http://bit.ly/2uAaTff) Further company coverage:

Aug 07 2017

BRIEF-ImmunoGen reports recent progress and second quarter 2017 operating results

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Jul 28 2017

BRIEF-Immunogen and Sanofi amend license agreements

* Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen's technology

May 30 2017

ImmunoGen drug moving ahead in single-agent, combination trials

Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

ImmunoGen drug moving ahead in single-agent, combination trials

May 17 Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

May 17 2017

BRIEF-Immunogen reports Q1 loss per share of $0.20

* Immunogen reports recent progress and first quarter 2017 operating results

May 05 2017

BRIEF-Highbridge Capital Management reports 5.34 pct passive stake in Immunogen

* Highbridge Capital Management Reports 5.34 pct passive stake in Immunogen Inc as of April 13 Source text: (http://bit.ly/2opbbaB) Further company coverage:

Apr 24 2017

Competitors

Earnings vs. Estimates